Otros idiomas ProMIS Neurosciences, Inc.

Acciones

PMN

CA74346M4065

Diferido Nasdaq Otros sitios de cotización 22:30:00 09/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,79 ^USD	-6,99 %		-9,82 %	+55,65 %

30/04	ProMIS Neurosciences, Inc. publica un estudio que destaca la selectividad de los oligómeros y el beneficio de los anticuerpos dirigidos contra el beta-amiloide	CI
09/04	ProMIS Neurosciences Inc. publica en el Journal of Biological Chemistry la interacción entre proteínas patógenas como diana de tratamiento para la ELA	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30/04
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30/04
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS	09/04
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	09/04
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	05/04
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	04/04
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights	01/04
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
ProMIS Neurosciences : Corporate Overview	29/03
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio	11/03
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference	22/02
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine	22/01
ProMIS Neurosciences Issues Letter to Shareholders	08/01
ProMIS Neurosciences, Inc. Announces Management Changes	03/01
ProMIS Neurosciences, Inc. Announces CEO Changes	03/01
ProMIS Neurosciences, Inc. Announces Leadership Transition	03/01
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20/12
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20/12
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease	20/11
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	20/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas ProMIS Neurosciences, Inc.

Acciones

PMN

CA74346M4065

Otros idiomas

Filtros